Fluorescence detection of zabofloxacin, a novel fluoroquinolone antibiotic, in plasma, bile, and urine by HPLC: The first oral and intravenous applications in a pharmacokinetic study of rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 3, 2011, Pages 291-305

  Jin, Hyo Eon ^a   Kang, In Hyul ^a   Shim, Chang Koo ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFORM; DW 224 A; ENROFLOXACIN; METHANOL; UNCLASSIFIED DRUG; ZABOFLOXACIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; FLUORESCENCE ANALYSIS; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRECIPITATION; RAT; ROOM TEMPERATURE; SOLVENT EXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79961148818     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3j592     Document Type: Article

References (21)

1. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother, 2003; 51 Suppl 1:13-20.
2. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents, 2000; 16:5-15.
3. Garcia-Garrote F, Cercenado E, Martin-Pedroviejo J, Cuevas O, Bouza E. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. J Antimicrob Chemother, 2001; 47:681-4.
4. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern G V. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother, 2001; 45:673-8.
5. Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents, 2010; 36:97-8.
6. Kim HJ, Seol MJ, Park HS, Choi DR, Seong SK, Shin HK, Kwak JH. Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae. J Antimicrob Chemother, 2006; 57:1256-8.
7. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother, 2006; 50:2261-64.
8. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am, 1995; 9:715-30.
9. Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA. Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Diagn Microbiol Infect Dis, 2008; 62:110-2.
10. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents, 2009; 34:15-20.
11. Jin HE, Lee KR, Kang IH, Chung SJ, Shim CK. Determination of zabofloxacin in rat plasma by liquid chromatography with mass spectrometry and its application to pharmacokinetic study. J Pharm Biomed Anal, 2011; 54:873-7.
12. USFDA. U.S. Department of Health & Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation. 2001.
13. Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ, Shim CK. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res, 2009; 26:549-59.
14. Gibaldi M, Perrier D. Pharmacokinetics, 2nd revised and expanded,. Informa HealthCare, New York, 1982:409-16.
15. Han J, Kim JC, Chung MK, Kim B, Choi DR. Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs. Biol Pharm Bull, 2003; 26:832-9.
16. Wang H, Liao ZX, Chen M, Hu XL. Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats. Pharmacol Res, 2006; 53:28-34.
17. Nouaille-Degorce B, Veau C, Dautrey S, Tod M, Laouari D, Carbon C, Farinotti R. Influence of renal failure on ciprofloxacin pharmacokinetics in rats. Antimicrob Agents Chemother, 1998; 42:289-92.
18. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother, 1986;30:444-6.
19. Janknegt R. Fluoroquinolones. Adverse reactions during clinical trials and postmarketing surveillance. Pharm Weekbl Sci, 1989; 11:124-7.
20. Kashida Y, Kato M. Toxic effects of quinolone antibacterial agents on the musculoskeletal system injuvenile rats. Toxicol Pathol, 1997; 25:635-43. 21.
21. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis, 1999; 28:299-308.